section name header

Pronunciation

LYE-doe-kane/PRI-loe-kane

Classifications

Therapeutic Classification: anesthetics (topical/local)

Indications

REMS


Action

  • Produces local anesthesia by inhibiting transport of ions across neuronal membranes, thereby preventing initiation and conduction of normal nerve impulses. Combination of two anesthetics is applied as a system consisting of a cream under an occlusive dressing. Active drug is released into the dermal and epidermal skin layers, resulting in accumulation of local anesthetic in the regions of dermal pain receptors and nerve endings.
Therapeutic effects:
  • Anesthetic action localized to the area of the application.

Pharmacokinetics

Absorption: Small amounts are systemically absorbed.

Distribution: Small amounts absorbed are widely distributed and cross the placenta and blood-brain barrier.

Metabolism/Excretion: Lidocaine: mostly metabolized by the liver. Prilocaine: metabolized by the liver and kidneys.

Half-Life: Lidocaine: 90–120 min (topical cream); 2–6 hr (periodontal gel): Prilocaine: 10–50 min (topical cream); 2–6 hr (periodontal gel).

Time/Action Profile

(local anesthesia)

ROUTEONSETPEAKDURATION
Topical1 hr (cream); 30 sec (periodontal gel)3 hr (cream)1–2 hr (cream) 20 min (periodontal gel)

Following removal of occlusive dressing.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Hemat: methemoglobinemia

Local: blanching, redness, alteration in temperature sensation, edema, hyperpigmentation, itching, rash

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Route/Dosage

Topical Cream

Periodontal Gel

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Oraqix

Canadian Brand Names

EMLA

Code

NDC Code